Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
The behavioral effects of L-dopa or cabergoline alone were compared with those of the joint administration of the two drugs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys with attention to the induction of hyperactivity and dyskinesia. Cabergoline alone at 0.2 mg/kg or less improved in a dose-dependent fashion the parkinsonism without inducing hyperactivity and dyskinesia following a single subcutaneous injection. L-dopa alone improved the parkinsonism, but induced hyperactivity and dyskinesia, depending on the dose applied. Doses required for 50% amelioration by L-dopa and cabergoline were 10 and 0.038 mg/kg, s.c., respectively. With low doses (50%-amelioration doses), cabergoline or L-dopa alone improved the parkinsonism without induction of hyperactivity and dyskinesia, but the duration of action was brief. Cabergoline in combination with L-dopa was highly effective in improving motor disability without induction of hyperactivity and dyskinesia. Moreover, the duration of action was more prolonged with the coadministration than with the single administration of each drug. These findings suggest that the combined therapy with low doses of L-dopa and cabergoline is beneficial for treating patients with advanced Parkinson's disease.
Arai
N
N
Pharmacological Laboratories, Kissei Pharmaceutical Co. Ltd., Nagano, Japan.
Isaji
M
M
Kojima
M
M
Mizuta
E
E
Kuno
S
S
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D000077465:Cabergoline; D004347:Drug Interactions; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology; D004873:Ergolines / Q000494:pharmacology*; D006948:Hyperkinesis / Q000139:chemically induced / Q000503:physiopathology; D007980:Levodopa / Q000494:pharmacology*; D008252:Macaca fascicularis; D009068:Movement / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents; D004873:Ergolines; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000077465:Cabergoline